Celemics Inc

Celemics Inc

331920 · KQ · Healthcare / Medical Devices

7,420.00KRW-260.00 (-3.39%)

Price History

Full chart

Market Stats

Previous Close7,680.00
Open7,680.00
Day Range6,950.00 – 7,810.00
52-Week Range2,535.00 – 19,840.00
Volume94.45K
Market Cap119.31B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta-0.04
50-Day Avg10,971.80
200-Day Avg9,764.78

About

Celemics, Inc. designs, manufactures, and distributes sequencing kits in South Korea. The company offers whole exome sequencing panels; NGS target enrichment panels; customized and ready-to-use enrichment panels; and modular accessories, including library preparation kits, double standard Cdna synthesis, hybridization enhancer, celan-up and streptavidin beads, CeleNM beads, and polymerase. It also provides celemics analysis, whole exome sequencing, customized NGS panels, sequencing, bioinformatics, biopharma, and custom NGS assay development services. Its products are used in oncology, liquid biopsy, biopharma solutions, inherited diseases, pharmacogenomics, virus research, agrigenomics, RNA sequencing, epigenetics, metagenomic sequencing, antibody discovery, and bioinformatics applications. The company was founded in 2010 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOYoung-hoon Lee
  • Employees46
  • HeadquartersBuilding A, Seoul, South Korea, 08506, Korea
  • Websitehttps://www.celemics.com

Leadership

  • Young-hoon LeeChairman & Co-CEO
  • Mr. Hyo-ki KimCo-Chief Executive Officer · b. 1983
  • Jong Gap ParkExecutive Director · b. 1965
  • MyeongKi JeongExecutive Director · b. 1974

Financials

Income Statement

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--2.06B2.52B5.14B5.27B8.08B8.73B6.58B6.72B5.77B
Growth (%)---+22.28%+103.75%+2.41%+53.54%+7.97%-24.65%+2.15%-14.16%
Cost of Revenue--1.79B2.31B4.38B4.18B5.25B6.31B5.06B3.04B2.90B
Gross Profit--277.06M213.21M758.35M1.09B2.83B2.42B1.52B3.68B2.87B
Gross Margin--13.43%8.45%14.75%20.63%35.05%27.76%23.15%54.72%49.71%
Operating Expense--3.82B4.34B5.82B5.98B8.85B8.16B7.29B5.58B6.19B
Operating Income---3.54B-4.12B-5.06B-4.89B-6.02B-5.73B-5.77B-1.90B-3.32B
Operating Margin---171.46%-163.43%-98.40%-92.95%-74.45%-65.69%-87.73%-28.32%-57.63%
EBITDA--------3.85B-2.98B13.08B-3.30B
EBITDA Margin--------44.09%-45.29%194.74%-57.24%
Net Income---1.72B-19.55B-2.26B-4.71B-5.24B-4.80B-3.88B12.27B-4.04B
Net Income Margin---83.42%-774.69%-43.87%-89.50%-64.79%-54.95%-58.92%182.56%-69.98%
R&D-----1.49B2.66B2.21B1.31B966.02M1.04B
R&D as % of Total Revenue-----28.33%32.89%25.33%19.88%14.38%18.02%
Interest Expense0000033.93M34.72M53.86M39.83M26.64M15.21M
Interest Expense % of Total Revenue--0.00%0.00%0.00%0.64%0.43%0.62%0.61%0.40%0.26%

Balance Sheet

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets--5.49B8.77B7.20B30.60B26.90B22.21B18.12B29.41B24.41B
Total Liabilities--16.15B38.97B2.04B1.24B3.51B3.62B2.24B2.23B1.39B
Total Equity---10.66B-30.20B5.16B29.36B23.39B18.59B15.88B27.18B23.02B
Cash--1.29B1.52B696.07M2.63B5.98B2.25B2.58B3.96B3.21B
Total Debt--9.00B15.32B925.50M20.02M-----

Cash Flow

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.48B-3.78B-3.72B-5.34B-5.37B-4.55B-3.20B-4.15B-4.53B-380.19M-3.60B
Investing Cash Flow-762.23M-508.66M-1.04B-2.13B2.31B-21.74B1.44B893.69M5.28B2.04B-
Financing Cash Flow1.93B5.28B4.90B8.01B2.18B28.05B-109.01M-475.72M-406.50M-367.58M-
Capital Expenditure595.01M369.79M703.91M42.91M138.12M421.87M574.22M550.87M219.25M116.75M165.79M
Free Cash Flow------4.97B-3.77B-4.70B-4.75B-496.94M-3.76B
FCF to OCF-----109.27%117.94%113.28%104.84%130.71%104.61%

Earnings

Report DateNov 13, 2020Mar 16, 2021May 17, 2021Aug 17, 2021Nov 15, 2021Dec 31, 2021May 13, 2022Aug 16, 2022Nov 14, 2022Mar 21, 2023May 15, 2023Aug 16, 2023Nov 14, 2023Mar 21, 2024May 17, 2024Aug 14, 2024Nov 12, 2024Mar 19, 2025May 15, 2025Aug 12, 2025Nov 12, 2025Mar 17, 2026May 13, 2026Jun 30, 2026
EPS Estimate------------------------
EPS Actual-146.00-131.54-182.63-216.88-177.78-68.84-65.20-164.69-193.53-164.14-150.83-197.79-163.1534.01-46.621521.241172.13-1144.28-275.29-353.65-186.85-99.76-740.70-535.05
Surprise------------------------
TimingPre-marketPre-market-After-hoursAfter-hours-Pre-marketPre-market-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap119.31B
Enterprise Value105.01B
Trailing P/E0.00
Forward P/E0.00
Price / Sales22.86
Price / Book4.18
Revenue (TTM)5.22B
Gross Profit (TTM)2.23B
EBITDA-3.21B
Profit Margin-194.78%
Operating Margin-67.17%
Return on Equity-38.80%
Return on Assets-6.67%
Shares Outstanding11.18M
Shares Float7.94M
Beta-0.04
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%